Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,857
archived clinical trials in
Hot Flash

Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic Cancer Care at Regional Cancer Center
mi
from
Eau Claire, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic Cancer Care at Regional Cancer Center
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic at Saint Michael's Hospital
mi
from
Stevens Point, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic at Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Venlafaxine and Hypnosis or Focused Attention In Treating Patients With Hot Flashes
Evaluation of a Biobehavioral Intervention for Hot Flashes
Status: Enrolling
Updated:  12/15/2016
The Mayo Clinic
mi
from
Rochester, MN
Venlafaxine and Hypnosis or Focused Attention In Treating Patients With Hot Flashes
Evaluation of a Biobehavioral Intervention for Hot Flashes
Status: Enrolling
Updated: 12/15/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.
A Placebo Controlled Double Blinded Prospective Study to Investigate the Usefulness of Omega 3 Fatty Acids in the Relief of Vasomotor Symptoms of Menopausal Women
Status: Enrolling
Updated:  5/9/2017
Christiana Care Health Systems
mi
from
Newark, DE
Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.
A Placebo Controlled Double Blinded Prospective Study to Investigate the Usefulness of Omega 3 Fatty Acids in the Relief of Vasomotor Symptoms of Menopausal Women
Status: Enrolling
Updated: 5/9/2017
Christiana Care Health Systems
mi
from
Newark, DE
Click here to add this to my saved trials
Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause
Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause
Status: Enrolling
Updated:  5/11/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause
Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause
Status: Enrolling
Updated: 5/11/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Chandler, AZ
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Glendale, AZ
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Scottsdale, AZ
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Tucson, AZ
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Poway, CA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Poway, CA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
San Diego, CA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Aurora, CO
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Boulder, CO
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Boulder, CO
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Denver, CO
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Wheat Ridge, CO
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Crystal River, FL
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Crystal River, FL
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Miami, FL
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Pinellas Park, FL
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Atlanta, GA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Savannah, GA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Overland Park, KA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Louisville, KY
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Sunset, LA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Sunset, LA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Billings, MT
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Billings, MT
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
New Brunswick, NJ
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Cleveland, OH
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Eugene, OR
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Portland, OR
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Hilton Head Island, SC
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Hilton Head Island, SC
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Dallas, TX
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Midland, TX
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Midland, TX
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Norfolk, VA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
mi
from
Seattle, WA
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials